Silence Therapeutics Plc
LONDON, July 7, 2010 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company")
announces the issuance of United States patent 7,750,144, titled Methods and
Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the
United States Patent and Trademark Office (USPTO).
LONDON, June 9, 2010 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company")
announces the issuance of United States patent 7,732,593, titled Methods and
Compositions For Controlling Efficacy of RNA Silencing, by the United States
Patent and Trademark Office (USPTO).
LONDON, May 26, 2010 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company")
announces the issuance of United States patent 7,723,316, titled Compositions
and Methods of RNAi Therapeutics For Treatment of Cancer and Other
Neovascularization Disease, by the United States Patent and Trademark Office
(USPTO).
LONDON, May 11, 2010 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company")
announces that Philip Haworth, Ph.D., chief executive officer, will present
corporate updates at two upcoming industry and financial conferences.
LONDON, May 5, 2010 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company")
announces the promotion of Jorg Kaufmann, Ph.D., to the position of vice
president of research.
More News
- Silence Therapeutics plc Unaudited Preliminary Results for the Year Ended 31 December 2009
- Silence Therapeutics plc Notification of Results
- Silence Therapeutics and AstraZeneca Extend siRNA Delivery Collaboration
- Appointment Adds Key Financial and Fundraising Experience
- Company Consolidates Research Activities in Berlin and Operations in Palo Alto
- Companies to Examine Delivery of RNAi Therapeutics to Additional Disease Targets
- Silence Therapeutics Receives Notice of Allowance for RNA Interference (RNAi) Patent Covering Novel Cancer Target
- Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
